Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs

The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2017-01, Vol.68 (1), p.345-358
Main Authors: Naggie, Susanna, Muir, Andrew J
Format: Article
Language:English
Subjects:
Administration, Oral
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Antiviral drugs
Coinfection - drug therapy
decompensated cirrhosis, liver transplant
Drug dosages
Drug Resistance, Viral
Drug Therapy, Combination - methods
end-stage liver disease
Genotype
HCV, direct-acting antiviral, HIV HCV coinfection
Hepacivirus - genetics
Hepatitis
Hepatitis C
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C - physiopathology
Hepatitis C virus
HIV Infections - drug therapy
Humans
Kidney Failure, Chronic - surgery
Kidney Failure, Chronic - virology
kidney transplant
Lentivirus
Liver Cirrhosis - surgery
Liver Cirrhosis - virology
Liver Transplantation
Recurrence
Retroviridae
Secondary Prevention - methods
Transplants & implants
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV HCV coinfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease. We highlight the greatest successes of combination DAA therapies, discuss the ongoing challenges, and identify the remaining patient subgroups with unmet medical needs.
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev-med-052915-015720